Celldex Therapeutics, Inc.

NasdaqCM:CLDX 株式レポート

時価総額:US$1.7b

Celldex Therapeutics 過去の業績

過去 基準チェック /06

Celldex Therapeuticsの収益は年間平均-26.1%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間19.1% 5.9%割合で 増加しています。

主要情報

-26.1%

収益成長率

1.2%

EPS成長率

Biotechs 業界の成長17.0%
収益成長率5.9%
株主資本利益率-19.6%
ネット・マージン-1,544.5%
前回の決算情報30 Sep 2024

最近の業績更新

Recent updates

Here's Why Celldex Therapeutics, Inc.'s (NASDAQ:CLDX) CEO Compensation Is The Least Of Shareholders' Concerns

Jun 07
Here's Why Celldex Therapeutics, Inc.'s (NASDAQ:CLDX) CEO Compensation Is The Least Of Shareholders' Concerns

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

Jun 05
We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

Jul 07
We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

An Intrinsic Calculation For Celldex Therapeutics, Inc. (NASDAQ:CLDX) Suggests It's 34% Undervalued

Apr 21
An Intrinsic Calculation For Celldex Therapeutics, Inc. (NASDAQ:CLDX) Suggests It's 34% Undervalued

Companies Like Celldex Therapeutics (NASDAQ:CLDX) Are In A Position To Invest In Growth

Feb 27
Companies Like Celldex Therapeutics (NASDAQ:CLDX) Are In A Position To Invest In Growth

We're Not Very Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Rate

Sep 07
We're Not Very Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Rate

Celldex begins dosing in mid-stage study of barzolvolimab for skin disorder

Jul 21

Celldex: Barzolvolimab Plus Bispecific Antibodies Advancement

Jul 14

Celldex Therapeutics (NASDAQ:CLDX) Is In A Good Position To Deliver On Growth Plans

May 25
Celldex Therapeutics (NASDAQ:CLDX) Is In A Good Position To Deliver On Growth Plans

Are Investors Undervaluing Celldex Therapeutics, Inc. (NASDAQ:CLDX) By 31%?

Feb 03
Are Investors Undervaluing Celldex Therapeutics, Inc. (NASDAQ:CLDX) By 31%?

Celldex: Pipeline Of Drug Candidates Is Worth A Look

Feb 01

Celldex Therapeutics: A Best Price-Positioned Biotech Stock As Seen By Market-Makers

Sep 23

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Easily Afford To Drive Business Growth

Sep 15
We Think Celldex Therapeutics (NASDAQ:CLDX) Can Easily Afford To Drive Business Growth

収支内訳

Celldex Therapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NasdaqCM:CLDX 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
30 Sep 2410-154370
30 Jun 248-1503515
31 Mar 246-145330
31 Dec 237-141310
30 Sep 234-125290
30 Jun 233-1132748
31 Mar 233-119270
31 Dec 222-112270
30 Sep 221-106270
30 Jun 221-100260
31 Mar 224-77230
31 Dec 215-71200
30 Sep 218-72180
30 Jun 219-66160
31 Mar 215-64150
31 Dec 207-60140
30 Sep 205-48140
30 Jun 204-46140
31 Mar 205-46140
31 Dec 194-51150
30 Sep 194-50170
30 Jun 195-46170
31 Mar 197-50190
31 Dec 1810-151190
30 Sep 1811-146210
30 Jun 1814-165220
31 Mar 1815-177230
31 Dec 1713-93250
30 Sep 1711-121270
30 Jun 179-125290
31 Mar 177-128300
31 Dec 167-129340
30 Sep 167-129350
30 Jun 166-131370
31 Mar 166-132370
31 Dec 155-127340
30 Sep 155-126290
30 Jun 155-122260
31 Mar 154-118220
31 Dec 144-118210
30 Sep 143-108190
30 Jun 143-103180
31 Mar 142-94160
31 Dec 134-82150

質の高い収益: CLDXは現在利益が出ていません。

利益率の向上: CLDXは現在利益が出ていません。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: CLDXは利益が出ておらず、過去 5 年間で損失は年間26.1%の割合で増加しています。

成長の加速: CLDXの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: CLDXは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 16.6% ) と比較することは困難です。


株主資本利益率

高いROE: CLDXは現在利益が出ていないため、自己資本利益率 ( -19.61% ) はマイナスです。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘